世界のヘパリン起因性血小板減少症 (HIT) 治療市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-4300
• 出版社/出版日：QYResearch / 2021年6月
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、106ページ
• 納品方法：Eメール（納期：3日）
• 産業分類：医療

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

QYResearch社発行の本調査レポートでは、ヘパリン起因性血小板減少症 (HIT) 治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（診断、治療）、用途別市場規模（病院、診断センター、専門医クリニック、病院薬局）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。
・市場概要
・ヘパリン起因性血小板減少症 (HIT) 治療の市場動向
・企業の競争状況、市場シェア
・ヘパリン起因性血小板減少症 (HIT) 治療の種類別市場規模と予測2016-2027（診断、治療）
・ヘパリン起因性血小板減少症 (HIT) 治療の用途別市場規模と予測2016-2027（病院、診断センター、専門医クリニック、病院薬局）
・ヘパリン起因性血小板減少症 (HIT) 治療の北米市場規模2016-2027（アメリカ、カナダ）
・ヘパリン起因性血小板減少症 (HIT) 治療の欧州市場規模2016-2027（ドイツ、フランス、イギリス等）
・ヘパリン起因性血小板減少症 (HIT) 治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等）
・ヘパリン起因性血小板減少症 (HIT) 治療の中南米市場規模2016-2027（メキシコ、ブラジル）
・ヘパリン起因性血小板減少症 (HIT) 治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等）
・主要企業情報（Bayer Healthcare Pharmaceuticals Inc.、Pfizer Inc.、Janssen Pharmaceuticals, Inc.、Bristol-Myers Squibb Company、Eisai Co., Ltd、LEO Pharma A/S、Mylan N.V.、Sanofi S.A.、Teva Pharmaceutical Industries Ltd.、Fresenius Kabi AG、Syntex S.A.、Celgene Corporation）
・結論

Market Analysis and Insights: Global Heparin-Induced Thrombocytopenia (HIT) Treatment Market
The global Heparin-Induced Thrombocytopenia (HIT) Treatment market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Heparin-Induced Thrombocytopenia (HIT) Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Heparin-Induced Thrombocytopenia (HIT) Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Heparin-Induced Thrombocytopenia (HIT) Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Heparin-Induced Thrombocytopenia (HIT) Treatment market.

Global Heparin-Induced Thrombocytopenia (HIT) Treatment Scope and Market Size
Heparin-Induced Thrombocytopenia (HIT) Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Heparin-Induced Thrombocytopenia (HIT) Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Diagnosis
Treatment

Segment by Application
Hospital
Diagnostic Center
Specialist Clinic
Hospital Pharmacy

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Bayer Healthcare Pharmaceuticals Inc.
Pfizer Inc.
Janssen Pharmaceuticals, Inc.
Bristol-Myers Squibb Company
Eisai Co., Ltd
LEO Pharma A/S
Mylan N.V.
Sanofi S.A.
Teva Pharmaceutical Industries Ltd.
Fresenius Kabi AG
Syntex S.A.
Celgene Corporation

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Diagnosis
1.2.3 Treatment
1.3 Market by Application
1.3.1 Global Heparin-Induced Thrombocytopenia (HIT) Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Diagnostic Center
1.3.4 Specialist Clinic
1.3.5 Hospital Pharmacy
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Heparin-Induced Thrombocytopenia (HIT) Treatment Market Perspective (2016-2027)
2.2 Heparin-Induced Thrombocytopenia (HIT) Treatment Growth Trends by Regions
2.2.1 Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Heparin-Induced Thrombocytopenia (HIT) Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Heparin-Induced Thrombocytopenia (HIT) Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Heparin-Induced Thrombocytopenia (HIT) Treatment Industry Dynamic
2.3.1 Heparin-Induced Thrombocytopenia (HIT) Treatment Market Trends
2.3.2 Heparin-Induced Thrombocytopenia (HIT) Treatment Market Drivers
2.3.3 Heparin-Induced Thrombocytopenia (HIT) Treatment Market Challenges
2.3.4 Heparin-Induced Thrombocytopenia (HIT) Treatment Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Heparin-Induced Thrombocytopenia (HIT) Treatment Players by Revenue
3.1.1 Global Top Heparin-Induced Thrombocytopenia (HIT) Treatment Players by Revenue (2016-2021)
3.1.2 Global Heparin-Induced Thrombocytopenia (HIT) Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Heparin-Induced Thrombocytopenia (HIT) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Heparin-Induced Thrombocytopenia (HIT) Treatment Revenue
3.4 Global Heparin-Induced Thrombocytopenia (HIT) Treatment Market Concentration Ratio
3.4.1 Global Heparin-Induced Thrombocytopenia (HIT) Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Heparin-Induced Thrombocytopenia (HIT) Treatment Revenue in 2020
3.5 Heparin-Induced Thrombocytopenia (HIT) Treatment Key Players Head office and Area Served
3.6 Key Players Heparin-Induced Thrombocytopenia (HIT) Treatment Product Solution and Service
3.7 Date of Enter into Heparin-Induced Thrombocytopenia (HIT) Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Heparin-Induced Thrombocytopenia (HIT) Treatment Breakdown Data by Type
4.1 Global Heparin-Induced Thrombocytopenia (HIT) Treatment Historic Market Size by Type (2016-2021)
4.2 Global Heparin-Induced Thrombocytopenia (HIT) Treatment Forecasted Market Size by Type (2022-2027)

5 Heparin-Induced Thrombocytopenia (HIT) Treatment Breakdown Data by Application
5.1 Global Heparin-Induced Thrombocytopenia (HIT) Treatment Historic Market Size by Application (2016-2021)
5.2 Global Heparin-Induced Thrombocytopenia (HIT) Treatment Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size (2016-2027)
6.2 North America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Type
6.2.1 North America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Type (2016-2021)
6.2.2 North America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Type (2022-2027)
6.2.3 North America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Type (2016-2027)
6.3 North America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Application
6.3.1 North America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Application (2016-2021)
6.3.2 North America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Application (2022-2027)
6.3.3 North America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Application (2016-2027)
6.4 North America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Country
6.4.1 North America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Country (2016-2021)
6.4.2 North America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size (2016-2027)
7.2 Europe Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Type
7.2.1 Europe Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Type (2016-2021)
7.2.2 Europe Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Type (2022-2027)
7.2.3 Europe Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Type (2016-2027)
7.3 Europe Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Application
7.3.1 Europe Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Application (2016-2021)
7.3.2 Europe Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Application (2022-2027)
7.3.3 Europe Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Application (2016-2027)
7.4 Europe Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Country
7.4.1 Europe Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Country (2016-2021)
7.4.2 Europe Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size (2016-2027)
8.2 Asia-Pacific Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Type
8.2.1 Asia-Pacific Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Application
8.3.1 Asia-Pacific Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Region
8.4.1 Asia-Pacific Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size (2016-2027)
9.2 Latin America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Type
9.2.1 Latin America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Type (2016-2027)
9.3 Latin America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Application
9.3.1 Latin America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Application (2016-2027)
9.4 Latin America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Country
9.4.1 Latin America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size (2016-2027)
10.2 Middle East & Africa Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Type
10.2.1 Middle East & Africa Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Application
10.3.1 Middle East & Africa Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Country
10.4.1 Middle East & Africa Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Bayer Healthcare Pharmaceuticals Inc.
11.1.1 Bayer Healthcare Pharmaceuticals Inc. Company Details
11.1.2 Bayer Healthcare Pharmaceuticals Inc. Business Overview
11.1.3 Bayer Healthcare Pharmaceuticals Inc. Heparin-Induced Thrombocytopenia (HIT) Treatment Introduction
11.1.4 Bayer Healthcare Pharmaceuticals Inc. Revenue in Heparin-Induced Thrombocytopenia (HIT) Treatment Business (2016-2021)
11.1.5 Bayer Healthcare Pharmaceuticals Inc. Recent Development
11.2 Pfizer Inc.
11.2.1 Pfizer Inc. Company Details
11.2.2 Pfizer Inc. Business Overview
11.2.3 Pfizer Inc. Heparin-Induced Thrombocytopenia (HIT) Treatment Introduction
11.2.4 Pfizer Inc. Revenue in Heparin-Induced Thrombocytopenia (HIT) Treatment Business (2016-2021)
11.2.5 Pfizer Inc. Recent Development
11.3 Janssen Pharmaceuticals, Inc.
11.3.1 Janssen Pharmaceuticals, Inc. Company Details
11.3.2 Janssen Pharmaceuticals, Inc. Business Overview
11.3.3 Janssen Pharmaceuticals, Inc. Heparin-Induced Thrombocytopenia (HIT) Treatment Introduction
11.3.4 Janssen Pharmaceuticals, Inc. Revenue in Heparin-Induced Thrombocytopenia (HIT) Treatment Business (2016-2021)
11.3.5 Janssen Pharmaceuticals, Inc. Recent Development
11.4 Bristol-Myers Squibb Company
11.4.1 Bristol-Myers Squibb Company Company Details
11.4.2 Bristol-Myers Squibb Company Business Overview
11.4.3 Bristol-Myers Squibb Company Heparin-Induced Thrombocytopenia (HIT) Treatment Introduction
11.4.4 Bristol-Myers Squibb Company Revenue in Heparin-Induced Thrombocytopenia (HIT) Treatment Business (2016-2021)
11.4.5 Bristol-Myers Squibb Company Recent Development
11.5 Eisai Co., Ltd
11.5.1 Eisai Co., Ltd Company Details
11.5.2 Eisai Co., Ltd Business Overview
11.5.3 Eisai Co., Ltd Heparin-Induced Thrombocytopenia (HIT) Treatment Introduction
11.5.4 Eisai Co., Ltd Revenue in Heparin-Induced Thrombocytopenia (HIT) Treatment Business (2016-2021)
11.5.5 Eisai Co., Ltd Recent Development
11.6 LEO Pharma A/S
11.6.1 LEO Pharma A/S Company Details
11.6.2 LEO Pharma A/S Business Overview
11.6.3 LEO Pharma A/S Heparin-Induced Thrombocytopenia (HIT) Treatment Introduction
11.6.4 LEO Pharma A/S Revenue in Heparin-Induced Thrombocytopenia (HIT) Treatment Business (2016-2021)
11.6.5 LEO Pharma A/S Recent Development
11.7 Mylan N.V.
11.7.1 Mylan N.V. Company Details
11.7.2 Mylan N.V. Business Overview
11.7.3 Mylan N.V. Heparin-Induced Thrombocytopenia (HIT) Treatment Introduction
11.7.4 Mylan N.V. Revenue in Heparin-Induced Thrombocytopenia (HIT) Treatment Business (2016-2021)
11.7.5 Mylan N.V. Recent Development
11.8 Sanofi S.A.
11.8.1 Sanofi S.A. Company Details
11.8.2 Sanofi S.A. Business Overview
11.8.3 Sanofi S.A. Heparin-Induced Thrombocytopenia (HIT) Treatment Introduction
11.8.4 Sanofi S.A. Revenue in Heparin-Induced Thrombocytopenia (HIT) Treatment Business (2016-2021)
11.8.5 Sanofi S.A. Recent Development
11.9 Teva Pharmaceutical Industries Ltd.
11.9.1 Teva Pharmaceutical Industries Ltd. Company Details
11.9.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.9.3 Teva Pharmaceutical Industries Ltd. Heparin-Induced Thrombocytopenia (HIT) Treatment Introduction
11.9.4 Teva Pharmaceutical Industries Ltd. Revenue in Heparin-Induced Thrombocytopenia (HIT) Treatment Business (2016-2021)
11.9.5 Teva Pharmaceutical Industries Ltd. Recent Development
11.10 Fresenius Kabi AG
11.10.1 Fresenius Kabi AG Company Details
11.10.2 Fresenius Kabi AG Business Overview
11.10.3 Fresenius Kabi AG Heparin-Induced Thrombocytopenia (HIT) Treatment Introduction
11.10.4 Fresenius Kabi AG Revenue in Heparin-Induced Thrombocytopenia (HIT) Treatment Business (2016-2021)
11.10.5 Fresenius Kabi AG Recent Development
11.11 Syntex S.A.
11.11.1 Syntex S.A. Company Details
11.11.2 Syntex S.A. Business Overview
11.11.3 Syntex S.A. Heparin-Induced Thrombocytopenia (HIT) Treatment Introduction
11.11.4 Syntex S.A. Revenue in Heparin-Induced Thrombocytopenia (HIT) Treatment Business (2016-2021)
11.11.5 Syntex S.A. Recent Development
11.12 Celgene Corporation
11.12.1 Celgene Corporation Company Details
11.12.2 Celgene Corporation Business Overview
11.12.3 Celgene Corporation Heparin-Induced Thrombocytopenia (HIT) Treatment Introduction
11.12.4 Celgene Corporation Revenue in Heparin-Induced Thrombocytopenia (HIT) Treatment Business (2016-2021)
11.12.5 Celgene Corporation Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Diagnosis
Table 3. Key Players of Treatment
Table 4. Global Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global Heparin-Induced Thrombocytopenia (HIT) Treatment Market Share by Regions (2016-2021)
Table 8. Global Heparin-Induced Thrombocytopenia (HIT) Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global Heparin-Induced Thrombocytopenia (HIT) Treatment Market Share by Regions (2022-2027)
Table 10. Heparin-Induced Thrombocytopenia (HIT) Treatment Market Trends
Table 11. Heparin-Induced Thrombocytopenia (HIT) Treatment Market Drivers
Table 12. Heparin-Induced Thrombocytopenia (HIT) Treatment Market Challenges
Table 13. Heparin-Induced Thrombocytopenia (HIT) Treatment Market Restraints
Table 14. Global Heparin-Induced Thrombocytopenia (HIT) Treatment Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global Heparin-Induced Thrombocytopenia (HIT) Treatment Market Share by Players (2016-2021)
Table 16. Global Top Heparin-Induced Thrombocytopenia (HIT) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Heparin-Induced Thrombocytopenia (HIT) Treatment as of 2020)
Table 17. Ranking of Global Top Heparin-Induced Thrombocytopenia (HIT) Treatment Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by Heparin-Induced Thrombocytopenia (HIT) Treatment Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Heparin-Induced Thrombocytopenia (HIT) Treatment Product Solution and Service
Table 21. Date of Enter into Heparin-Induced Thrombocytopenia (HIT) Treatment Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 24. Global Heparin-Induced Thrombocytopenia (HIT) Treatment Revenue Market Share by Type (2016-2021)
Table 25. Global Heparin-Induced Thrombocytopenia (HIT) Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global Heparin-Induced Thrombocytopenia (HIT) Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size Share by Application (2016-2021) & (US$ Million)
Table 28. Global Heparin-Induced Thrombocytopenia (HIT) Treatment Revenue Market Share by Application (2016-2021)
Table 29. Global Heparin-Induced Thrombocytopenia (HIT) Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 30. Global Heparin-Induced Thrombocytopenia (HIT) Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 31. North America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 32. North America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 34. North America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 35. North America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 40. Europe Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 41. Europe Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 46. Asia-Pacific Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 52. Latin America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 53. Latin America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 58. Middle East & Africa Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 61. Bayer Healthcare Pharmaceuticals Inc. Company Details
Table 62. Bayer Healthcare Pharmaceuticals Inc. Business Overview
Table 63. Bayer Healthcare Pharmaceuticals Inc. Heparin-Induced Thrombocytopenia (HIT) Treatment Product
Table 64. Bayer Healthcare Pharmaceuticals Inc. Revenue in Heparin-Induced Thrombocytopenia (HIT) Treatment Business (2016-2021) & (US$ Million)
Table 65. Bayer Healthcare Pharmaceuticals Inc. Recent Development
Table 66. Pfizer Inc. Company Details
Table 67. Pfizer Inc. Business Overview
Table 68. Pfizer Inc. Heparin-Induced Thrombocytopenia (HIT) Treatment Product
Table 69. Pfizer Inc. Revenue in Heparin-Induced Thrombocytopenia (HIT) Treatment Business (2016-2021) & (US$ Million)
Table 70. Pfizer Inc. Recent Development
Table 71. Janssen Pharmaceuticals, Inc. Company Details
Table 72. Janssen Pharmaceuticals, Inc. Business Overview
Table 73. Janssen Pharmaceuticals, Inc. Heparin-Induced Thrombocytopenia (HIT) Treatment Product
Table 74. Janssen Pharmaceuticals, Inc. Revenue in Heparin-Induced Thrombocytopenia (HIT) Treatment Business (2016-2021) & (US$ Million)
Table 75. Janssen Pharmaceuticals, Inc. Recent Development
Table 76. Bristol-Myers Squibb Company Company Details
Table 77. Bristol-Myers Squibb Company Business Overview
Table 78. Bristol-Myers Squibb Company Heparin-Induced Thrombocytopenia (HIT) Treatment Product
Table 79. Bristol-Myers Squibb Company Revenue in Heparin-Induced Thrombocytopenia (HIT) Treatment Business (2016-2021) & (US$ Million)
Table 80. Bristol-Myers Squibb Company Recent Development
Table 81. Eisai Co., Ltd Company Details
Table 82. Eisai Co., Ltd Business Overview
Table 83. Eisai Co., Ltd Heparin-Induced Thrombocytopenia (HIT) Treatment Product
Table 84. Eisai Co., Ltd Revenue in Heparin-Induced Thrombocytopenia (HIT) Treatment Business (2016-2021) & (US$ Million)
Table 85. Eisai Co., Ltd Recent Development
Table 86. LEO Pharma A/S Company Details
Table 87. LEO Pharma A/S Business Overview
Table 88. LEO Pharma A/S Heparin-Induced Thrombocytopenia (HIT) Treatment Product
Table 89. LEO Pharma A/S Revenue in Heparin-Induced Thrombocytopenia (HIT) Treatment Business (2016-2021) & (US$ Million)
Table 90. LEO Pharma A/S Recent Development
Table 91. Mylan N.V. Company Details
Table 92. Mylan N.V. Business Overview
Table 93. Mylan N.V. Heparin-Induced Thrombocytopenia (HIT) Treatment Product
Table 94. Mylan N.V. Revenue in Heparin-Induced Thrombocytopenia (HIT) Treatment Business (2016-2021) & (US$ Million)
Table 95. Mylan N.V. Recent Development
Table 96. Sanofi S.A. Company Details
Table 97. Sanofi S.A. Business Overview
Table 98. Sanofi S.A. Revenue in Heparin-Induced Thrombocytopenia (HIT) Treatment Business (2016-2021) & (US$ Million)
Table 99. Sanofi S.A. Recent Development
Table 100. Teva Pharmaceutical Industries Ltd. Company Details
Table 101. Teva Pharmaceutical Industries Ltd. Business Overview
Table 102. Teva Pharmaceutical Industries Ltd. Heparin-Induced Thrombocytopenia (HIT) Treatment Product
Table 103. Teva Pharmaceutical Industries Ltd. Revenue in Heparin-Induced Thrombocytopenia (HIT) Treatment Business (2016-2021) & (US$ Million)
Table 104. Teva Pharmaceutical Industries Ltd. Recent Development
Table 105. Fresenius Kabi AG Company Details
Table 106. Fresenius Kabi AG Business Overview
Table 107. Fresenius Kabi AG Heparin-Induced Thrombocytopenia (HIT) Treatment Product
Table 108. Fresenius Kabi AG Revenue in Heparin-Induced Thrombocytopenia (HIT) Treatment Business (2016-2021) & (US$ Million)
Table 109. Fresenius Kabi AG Recent Development
Table 110. Syntex S.A. Company Details
Table 111. Syntex S.A. Business Overview
Table 112. Syntex S.A. Heparin-Induced Thrombocytopenia (HIT) Treatment Product
Table 113. Syntex S.A. Revenue in Heparin-Induced Thrombocytopenia (HIT) Treatment Business (2016-2021) & (US$ Million)
Table 114. Syntex S.A. Recent Development
Table 115. Celgene Corporation Company Details
Table 116. Celgene Corporation Business Overview
Table 117. Celgene Corporation Heparin-Induced Thrombocytopenia (HIT) Treatment Product
Table 118. Celgene Corporation Revenue in Heparin-Induced Thrombocytopenia (HIT) Treatment Business (2016-2021) & (US$ Million)
Table 119. Celgene Corporation Recent Development
Table 120. Research Programs/Design for This Report
Table 121. Key Data Information from Secondary Sources
Table 122. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Heparin-Induced Thrombocytopenia (HIT) Treatment Market Share by Type: 2020 VS 2027
Figure 2. Diagnosis Features
Figure 3. Treatment Features
Figure 4. Global Heparin-Induced Thrombocytopenia (HIT) Treatment Market Share by Application: 2020 VS 2027
Figure 5. Hospital Case Studies
Figure 6. Diagnostic Center Case Studies
Figure 7. Specialist Clinic Case Studies
Figure 8. Hospital Pharmacy Case Studies
Figure 9. Heparin-Induced Thrombocytopenia (HIT) Treatment Report Years Considered
Figure 10. Global Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 11. Global Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Heparin-Induced Thrombocytopenia (HIT) Treatment Market Share by Regions: 2020 VS 2027
Figure 13. Global Heparin-Induced Thrombocytopenia (HIT) Treatment Market Share by Regions (2022-2027)
Figure 14. Global Heparin-Induced Thrombocytopenia (HIT) Treatment Market Share by Players in 2020
Figure 15. Global Top Heparin-Induced Thrombocytopenia (HIT) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Heparin-Induced Thrombocytopenia (HIT) Treatment as of 2020
Figure 16. The Top 10 and 5 Players Market Share by Heparin-Induced Thrombocytopenia (HIT) Treatment Revenue in 2020
Figure 17. Global Heparin-Induced Thrombocytopenia (HIT) Treatment Revenue Market Share by Type (2016-2021)
Figure 18. Global Heparin-Induced Thrombocytopenia (HIT) Treatment Revenue Market Share by Type (2022-2027)
Figure 19. North America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 20. North America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Share by Type (2016-2027)
Figure 21. North America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Share by Application (2016-2027)
Figure 22. North America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Share by Country (2016-2027)
Figure 23. United States Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Canada Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Heparin-Induced Thrombocytopenia (HIT) Treatment Market Share by Type (2016-2027)
Figure 27. Europe Heparin-Induced Thrombocytopenia (HIT) Treatment Market Share by Application (2016-2027)
Figure 28. Europe Heparin-Induced Thrombocytopenia (HIT) Treatment Market Share by Country (2016-2027)
Figure 29. Germany Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. France Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. U.K. Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Italy Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Russia Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Nordic Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Heparin-Induced Thrombocytopenia (HIT) Treatment Market Share by Type (2016-2027)
Figure 37. Asia-Pacific Heparin-Induced Thrombocytopenia (HIT) Treatment Market Share by Application (2016-2027)
Figure 38. Asia-Pacific Heparin-Induced Thrombocytopenia (HIT) Treatment Market Share by Region (2016-2027)
Figure 39. China Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Japan Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. South Korea Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Southeast Asia Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. India Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Australia Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Share by Type (2016-2027)
Figure 47. Latin America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Share by Application (2016-2027)
Figure 48. Latin America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Share by Country (2016-2027)
Figure 49. Mexico Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Brazil Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Heparin-Induced Thrombocytopenia (HIT) Treatment Market Share by Type (2016-2027)
Figure 53. Middle East & Africa Heparin-Induced Thrombocytopenia (HIT) Treatment Market Share by Application (2016-2027)
Figure 54. Middle East & Africa Heparin-Induced Thrombocytopenia (HIT) Treatment Market Share by Country (2016-2027)
Figure 55. Turkey Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Saudi Arabia Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. UAE Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Bayer Healthcare Pharmaceuticals Inc. Revenue Growth Rate in Heparin-Induced Thrombocytopenia (HIT) Treatment Business (2016-2021)
Figure 59. Pfizer Inc. Revenue Growth Rate in Heparin-Induced Thrombocytopenia (HIT) Treatment Business (2016-2021)
Figure 60. Janssen Pharmaceuticals, Inc. Revenue Growth Rate in Heparin-Induced Thrombocytopenia (HIT) Treatment Business (2016-2021)
Figure 61. Bristol-Myers Squibb Company Revenue Growth Rate in Heparin-Induced Thrombocytopenia (HIT) Treatment Business (2016-2021)
Figure 62. Eisai Co., Ltd Revenue Growth Rate in Heparin-Induced Thrombocytopenia (HIT) Treatment Business (2016-2021)
Figure 63. LEO Pharma A/S Revenue Growth Rate in Heparin-Induced Thrombocytopenia (HIT) Treatment Business (2016-2021)
Figure 64. Mylan N.V. Revenue Growth Rate in Heparin-Induced Thrombocytopenia (HIT) Treatment Business (2016-2021)
Figure 65. Sanofi S.A. Revenue Growth Rate in Heparin-Induced Thrombocytopenia (HIT) Treatment Business (2016-2021)
Figure 66. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Heparin-Induced Thrombocytopenia (HIT) Treatment Business (2016-2021)
Figure 67. Fresenius Kabi AG Revenue Growth Rate in Heparin-Induced Thrombocytopenia (HIT) Treatment Business (2016-2021)
Figure 68. Syntex S.A. Revenue Growth Rate in Heparin-Induced Thrombocytopenia (HIT) Treatment Business (2016-2021)
Figure 69. Celgene Corporation Revenue Growth Rate in Heparin-Induced Thrombocytopenia (HIT) Treatment Business (2016-2021)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed

Global Chemotherapy Induced Thrombocytopenia Drugs Market Size, Status and Forecast 2021-2027
QFJ1-3999 2021年6月 99Pages
QYResearch社発行の本調査レポートでは、化学療法誘発性血小板減少症治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（経口薬、注射薬）、用途別市場規模（病院薬局、小売薬局、オンライン薬局）、主要地域別市場規模（北米、アメリカ、欧州、アジア...

世界のオピオイド誘発性副作用治療市場規模・現状・予測（2021年-2027年）

Global Opioid Induced Side Effects Treatment Market Size, Status and Forecast 2021-2027
QFJ1-5911 2021年6月 97Pages
QYResearch社発行の本調査レポートでは、オピオイド誘発性副作用治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（リスペリドン、メチルフェニデート、セチリジン、その他）、用途別市場規模（薬物過剰摂取治療、疼痛治療、その他）、主要地域別市場規...

世界の薬物誘発性聴器毒性治療市場規模・現状・予測（2021年-2027年）

Global Drug Induced Ototoxicity Treatment Market Size, Status and Forecast 2021-2027
QFJ1-4158 2021年6月 108Pages
QYResearch社発行の本調査レポートでは、薬物誘発性聴器毒性治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（代替療法、医薬品、補聴器、人工内耳、福祉機器（ALD））、用途別市場規模（蝸牛薬原因聴器毒性、前庭薬原因聴器毒性）、主要地域別市場...

世界の結核（TB）治療市場規模・現状・予測（2021年-2027年）

Global Tuberculosis (TB) Treatment Market Size, Status and Forecast 2021-2027
QFJ1-4987 2021年6月 95Pages
QYResearch社発行の本調査レポートでは、結核（TB）治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（イソニアジド、リファンピン（リファディン、リマクタン）、エタンブトール（ミアンブトール）、ピラジナミド）、用途別市場規模（活動性結核、潜...

世界の顕微鏡的多発血管炎（MPA）治療市場規模・現状・予測（2021年-2027年）

Global Microscopic Polyangiitis(MPA) Treatment Market Size, Status and Forecast 2021-2027
QFJ1-4506 2021年6月 100Pages
QYResearch社発行の本調査レポートでは、顕微鏡的多発血管炎（MPA）治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（アバコパン、免疫グロブリン、リツキシマブバイオシミラー、その他）、用途別市場規模（病院、クリニック、その他）、主要地域別...

世界の尿素サイクル異常症（UCD）治療市場規模・現状・予測（2021年-2027年）

Global Urea Cycle Disorders (UCD) Treatment Market Size, Status and Forecast 2021-2027
QFJ1-5000 2021年6月 88Pages
QYResearch社発行の本調査レポートでは、尿素サイクル異常症（UCD）治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（アミノ酸式、フェニル酪酸、安息香酸ナトリウム、その他）、用途別市場規模（病院薬局、小売薬局、オンライン薬局）、主要地域別...

世界の慢性難治性咳（CRC）治療市場規模・現状・予測（2021年-2027年）

Global Chronic Refractory Cough (CRC) Treatment Market Size, Status and Forecast 2021-2027
QFJ1-5661 2021年6月 95Pages
QYResearch社発行の本調査レポートでは、慢性難治性咳（CRC）治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（言語療法、理学療法）、用途別市場規模（病院、診療所、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓...

世界の原始神経外胚葉性腫瘍（PNET）治療市場規模・現状・予測（2021年-2027年）

Global Primitive Neuroectodermal Tumors (PNET) Treatment Market Size, Status and Forecast 2021-2027
QFJ1-4766 2021年6月 98Pages
QYResearch社発行の本調査レポートでは、原始神経外胚葉性腫瘍（PNET）治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（外科手術、化学療法、放射線療法）、用途別市場規模（病院、外来手術センター、その他）、主要地域別市場規模（北米、アメリ...

世界の化学療法による悪心＆嘔吐治療市場規模・現状・予測（2021年-2027年）

Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size, Status and Forecast 2021-2027
QFJ1-5654 2021年6月 115Pages
QYResearch社発行の本調査レポートでは、化学療法による悪心＆嘔吐治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（アロキシ（パロノセトロン）、キトリル（グラニセトロン）、エメンド（アプレピタント）、その他）、用途別市場規模（急性悪心＆嘔吐...

世界の骨髄性プロトポルフィリン症（EPP）治療市場規模・現状・予測（2021年-2027年）

Global Erythropoietic Protoporphyria (EPP) Treatment Market Size, Status and Forecast 2021-2027
QFJ1-4205 2021年6月 97Pages
QYResearch社発行の本調査レポートでは、骨髄性プロトポルフィリン症（EPP）治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（ホルモン療法、補助療法、光線療法）、用途別市場規模（病院薬局、ドラッグストア、小売薬局、オンライン薬局）、主要地...

世界の化学療法誘発性血小板減少症治療薬市場規模・現状・予測（2021年-2027年） Chemotherapy is the cancer treatment given to patients with different forms of the cancer. Various drugs such as alkylating agents, antimetabolites, targeted therapy, immunotherapy drugs, etc. are used for the cancer treatment. These chemotherapy agents acts against the cancerous as well as normal c…
世界のオピオイド誘発性副作用治療市場規模・現状・予測（2021年-2027年） Opioids are the class of drug that include strong pain relievers and illegal drugs such as heroin and illicit pain relievers for example hydrocodone, oxycodone, morphine and fentanyl. Also they are available legally on prescription. These drugs interact with opioid receptors on nerve cells in body a…
世界の薬物誘発性聴器毒性治療市場規模・現状・予測（2021年-2027年） Drug induced ototoxicity is defined as damage to the Cochlea and vestibule caused by the use or exposure to certain therapeutic or chemical drugs Common OTOTOXIC drugs are: aminoglycoside antibiotics, salicylic acid, quinine and loop diuretics, anti-tumor chemotherapy drugs. Market Analysis and Insi…
世界の化学療法による悪心＆嘔吐治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Chemotheraphy-induced Nausea and Vomitting Treatment Market The global Chemotheraphy-induced Nausea and Vomitting Treatment market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-sta…
世界の免疫性血小板減少症治療薬市場規模・現状・予測（2021年-2027年） Thrombocytopenia is a condition characterized by abnormally low levels of thrombocytes, also known as platelets, in the blood. End-users prefer biosimilars over biologics because of their low cost. The low cost of biosimilars can be attributed to the fewer number of clinical trials required for appr…